Mobilization of Stem Cells With AMD3100 (Plerixafor) in Multiple Myeloma Patients
Status:
Completed
Trial end date:
2008-01-01
Target enrollment:
Participant gender:
Summary
The purpose of this study is to determine whether the combination of AMD3100 (plerixafor) and
granulocyte colony-stimulating factor (G-CSF, generic name of filgrastim) is better than
G-CSF alone to mobilize and collect the optimal number of stem cells in multiple myeloma
patients for autologous transplantation.